Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Rare Disease market access in the MENA and Nordic regions

Rare Disease market access in the MENA and Nordic regions

FromPharma Market Access Insights - from Mtech Access


Rare Disease market access in the MENA and Nordic regions

FromPharma Market Access Insights - from Mtech Access

ratings:
Length:
59 minutes
Released:
May 10, 2024
Format:
Podcast episode

Description

Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region?In this webinar,  our Global Market Access team compare and contrast access opportunities and challenges for rare disease treatments in the differing markets of the Nordic and MENA regions, asking: what does this mean for your overarching market access strategy?Our Global Market Access experts explore contrasting regions to showcase the significant differences between international markets when it comes to: - Overall and rare disease patient populations - Access inequalities - Time to diagnosis - Access to innovation timelines - Healthcare funding - Health technology assessment frameworksRobert Taaffe (Consultant – Global Market Access) presents his research into the market access conditions in the MENA regions, with a focus on the rare disease reimbursement landscape in growth markets in Egypt, Saudi Arabia, and the United Arab Emirates.Michelle James (Associate Consultant – Global Market Access) showcases market access and reimbursement routes in the more established, yet smaller populations in the Nordic regions. Michelle will focus on access in Denmark, Sweden, and Norway.Clare Foy (Director – Global Market Access) leads our discussion on the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy.Learn more at and request a copy of the webinar slides at: https://mtechaccess.co.uk/rare-disease-market-access-nordic-and-mena/Discover how Mtech Access can support you with market access, pricing and reimbursement for rare disease treatments at: https://mtechaccess.co.uk/global-market-access-and-pricing/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
Released:
May 10, 2024
Format:
Podcast episode

Titles in the series (57)

We explore news and insights from global healthcare markets, advising how pharma and medtech need to respond and adapt their market access strategy in light of the latest insights from our experts. The podcast features insights from our associates across global healthcare, along with thought leadership from the market access and HEOR experts at Mtech Access. Our first series focuses on the NHS response to the COVID-19 pandemic.